Why the study?
Doxorubicin clinical utility is limited by fatal cardiotoxicity and difficult early diagnosis, necessitating understanding of underlying mechanisms to develop early intervention strategies before irreversible myocardial damage occurs.
Design
Review
Authors
Loading...
Urges mechanism-based early intervention strategies in DIC; leaves open specific therapeutic targets for prospective validation.
MicroRNAs show promise as diagnostic biomarkers and therapeutic targets for early intervention in doxorubicin-induced cardiomyopathy.
Chen et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: